Publication: A Bayesian response-adaptive trial in tuberculosis: The endTB trial
Purpose: To evaluate the use of Bayesian adaptive randomization for clinical trials of new treatments for multidrug-resistant tuberculosis.
Purpose: To evaluate the use of Bayesian adaptive randomization for clinical trials of new treatments for multidrug-resistant tuberculosis.
This MSF Access Campaign report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs.
We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.
This report was produced with endTB's support.
This 20-page guide is designed to provide all endTB stakeholders with a detailed presentation of the project's four goals.